Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 8Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Neoplasms 4Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Fallopian Tube Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1SCLC, Extensive Stage 1Recurrence 1Radiation Injuries 1Primary Myelofibrosis 1Polycythemia Vera 1Peritoneal Neoplasms 1Myoepithelioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liposarcoma, Myxoid 1

Interventions

Temozolomide 6Irinotecan 6Vincristine 3PM 01183 3Nivolumab 3X-Rays 2Cyclophosphamide 2temsirolimus 1talazoparib 1surufatinib 1silmitasertib 1seclidemstat 1rubitecan 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1irinotecan sucrosofate 1eribulin 1entrectinib 1efineptakin alfa 1dinutuximab 1copanlisib 1bempegaldesleukin 1anlotinib 1alovudine 1abemaciclib 1Zoledronic Acid 1Trabectedin 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Ewing × Topotecan × Clear all
NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡